Asuragen pancreatic cancer assay found effective

7 November 2011 (Last Updated November 7th, 2011 18:30)

Asuragen's microRNA-based test, miRInform Pancreas, has demonstrated improvements in the diagnosis of pancreatic ductal adenocarcinoma.

Asuragen's microRNA-based test, miRInform Pancreas, has demonstrated improvements in the diagnosis of pancreatic ductal adenocarcinoma.

The data from the multicentre study involving 186 subjects showed that the miRNA-based molecular test will improve the diagnostic accuracy of fine-needle aspiration cytology on indeterminate and suspicious specimens.

miRInform Pancreas, along with standard fine-needle aspiration cytology, allows pancreatic ductal adenocarcinoma to be diagnosed with 92.5% accuracy, as compared to 80.2% for fine-needle aspiration cytology alone.

Brigham and Women's Hospital Dr Darwin Conwell said that the microRNA-based molecular test helps to identify false negative cytology.

The molecular test will be available in the company's CLIA Laboratory from 1 December 2011.